Zanubrutinib
Zanubrutinib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Lymphoma、Mantle Cell Lymphoma、Follicular Lymphoma、Marginal Zone Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
3 项
已进入 III/IV 期
15 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- M.D. Anderson Cancer Center
- Alliance for Clinical Trials in Oncology
- H. Lee Moffitt Cancer Center and Research Institute
- BeOne Medicines
- BeiGene
- Christine Ryan
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Institute of Hematology & Blood Diseases Hospital, China
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、Puerto Rico、中国、Argentina、澳大利亚、奥地利、Brazil、法国、德国、意大利、日本、新西兰
正在招募患者的 Zanubrutinib 研究
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
不适用招募中美国Puerto RicoNCT05640102BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
II 期招募中美国NCT06854003A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
III 期招募中中国NCT07377578Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma
II 期招募中中国NCT07299149A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
III 期招募中美国Argentina澳大利亚奥地利NCT06742996Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
II 期招募中美国NCT05681195Epco, Zanu, Ritux for R/R FL or MZL
II 期招募中美国NCT06563596Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
II 期招募中澳大利亚NCT06812715A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
I 期 / II 期招募中美国澳大利亚Brazil中国NCT06634589Pola-ZR2P in Previously Untreated DLBCL
II 期招募中中国NCT06664411The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
III 期招募中中国NCT06522555Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)
不适用招募中意大利NCT06823960Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma
I 期招募中美国NCT06730542ZR-MTX for PIOL Phase II Trial
II 期招募中中国NCT06973811Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma
II 期招募中美国NCT06839053SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
不适用招募中荷兰NCT07021495Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
不适用招募中中国NCT07126678Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 Subtypes
II 期招募中中国NCT07608978Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHL
II 期招募中中国NCT06695013Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
II 期招募中美国NCT05890352Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
II 期招募中中国NCT07165769A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
II 期招募中中国NCT06136351A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
II 期招募中中国NCT05214391Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
II 期招募中英国NCT05635162
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。